What Psychiatric Drug Development Can Learn From Cardiology Drug Development: Placebo Can Detect an Increase in the...

Area of Science:

• Clinical Trials Methodology
• Medical Ethics
• Psychiatric Research

Background:

• Placebo controls are essential for understanding the natural course of illness.
• Previous columns discussed treatment as usual (TAU) in randomized controlled trials (RCTs) versus clinical practice.
• The Heisenberg Uncertainty Principle impacts psychiatric clinical trials, affecting care received in RCTs versus real-world practice.

Purpose of the Study:

• To demonstrate how placebo controls reveal deleterious effects of active treatments.
• To emphasize the need for objective, clinically meaningful endpoints in psychiatric trials.
• To illustrate that placebo encompasses all non-investigational care and natural illness progression.

Main Methods:

• Analysis of studies using placebo as a control.
• Comparison of objective endpoints (e.g., death, infection resolution) with subjective psychiatric endpoints.
• Application of the Heisenberg Uncertainty Principle to clinical trial design and interpretation.

Main Results:

• Placebo use identified an active treatment as harmful to patients.
• In one case, placebo showed an antibiotic did not alter outcomes due to infection nature and TAU.
• Objective endpoints are contrasted with subjective symptom-based measures common in psychiatry.

Conclusions:

• Placebo is a vital control, not an inert substance, encompassing all trial care and natural history.
• Psychiatric research must prioritize objective, clinically meaningful endpoints over subjective measures.
• Investigators and readers must account for the Heisenberg Principle in psychiatric RCTs.